Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3000 participants.
Also called NCT04700826
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 3,000 participants
- Registry
-
NCT04700826
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT04700826. Randomized; no masking; primary purpose prevention. Start 2021-06-01 (actual); primary completion 2027-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation
- Acronym
- DaRe2THINK
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Direct Oral Anticoagulants
- Lead sponsor
- University of Birmingham
- Collaborator
- Clinical Practice Research Datalink
- Collaborator
- University Hospital Birmingham NHS Foundation Trust
- Collaborator
- University of Oxford
- Collaborator
- London School of Economics and Political Science
- Collaborator
- Aston University
Record details
- Record id
cardio:ct-nct04700826- Content hash
36a7b0ecc31c6c6d0aea72835710fa59113e8035d9e7216e1bdd81ba60e048db